February 14, 2023
Takeda Pharmaceutical said on February 13 that it has filed its blood cancer drug Adcetris (brentuximab vedotin) for an additional indication of relapsed or refractory CD30-positive cutaneous T-cell lymphoma in Japan. The submission is supported by data from the PIII...read more